Medicare does not cover Restasis under Original Medicare, but it may be covered under Medicare Part D or Medicare Advantage plans if included in the plan’s formulary. However, costs and coverage details can vary significantly among different plans.
Understanding Medicare’s coverage for Restasis is crucial for beneficiaries managing chronic dry eye disease. While Original Medicare does not provide coverage for this medication, options exist through Medicare Part D and Medicare Advantage plans, but navigating these rules can be more complex than many expect, especially with varying costs and eligibility requirements.
Key Takeaways
- Original Medicare Part A and Part B do not cover prescription drugs taken at home, including Restasis.
- Coverage for Restasis under Medicare Part D depends on whether it is included on the plan’s formulary.
- In 2026, generic cyclosporine 0.05% eye drops are widely covered and typically placed on lower tiers in many plans.
- Beneficiaries may face out-of-pocket costs if Restasis is not covered by their plan’s formulary.
- Beneficiaries should regularly check their plan’s formulary, as coverage rules can change annually.
Understanding Medicare Coverage for Restasis
Original Medicare Does Not Cover Restasis
Original Medicare, which includes Part A and Part B, does not cover prescription drugs taken at home, including Restasis. However, beneficiaries can access prescription drug coverage through Medicare Part D, which may help pay for Restasis if it is included in the plan’s formulary.
Drug Tier Classifications Impact Costs
Medicare Part D plans classify drugs like Restasis into pricing tiers that significantly affect how much beneficiaries pay out-of-pocket. In 2026, generic cyclosporine 0.05% eye drops, which are often preferred over brand Restasis, are typically placed on Tier 1 or Tier 2 in many plans, resulting in lower costs for beneficiaries.
Cost Considerations for Restasis Under Medicare
Potential Out-of-Pocket Costs
If Restasis is covered under a Medicare Part D or Medicare Advantage plan, beneficiaries may be responsible for a copayment or coinsurance, which varies based on the plan’s formulary placement and the pharmacy used. Generally, higher-tier placement of Restasis on a formulary leads to higher out-of-pocket costs.
Annual Out-of-Pocket Limit Benefits
In 2026, Medicare beneficiaries will benefit from an annual out-of-pocket limit of approximately $2,100 for all covered prescription drugs, which helps cap total yearly spending on medications like Restasis. Many plans have moved generic Restasis to lower tiers, which is associated with reduced copayments after meeting a deductible.
Key Exceptions to Medicare Coverage Rules
Limitations on Coverage
Original Medicare generally does not cover self-administered outpatient prescription drugs obtained at home, including Restasis. If Restasis is not listed on a plan’s formulary, the plan may not provide coverage for it.
Prior Authorization and Restrictions
Coverage for Restasis can differ among Medicare Part D and Medicare Advantage plans, with some requiring prior authorization or imposing restrictions. Certain plans may have policies that prohibit the concurrent use of more than one prescription product for dry eye, which can complicate access to Restasis.
Eligibility Requirements for Restasis Coverage
Enrollment in Appropriate Plans
To receive coverage for Restasis, beneficiaries must be enrolled in a Medicare Part D plan or a Medicare Advantage plan that includes prescription drug coverage. Additionally, Restasis typically needs to be prescribed by a healthcare provider for the treatment of chronic dry eye disease.
Diagnosis and Prior Authorization Policies
Effective in 2026, prior authorization policies for dry eye medications, including Restasis, generally require a diagnosis such as moderate to severe keratoconjunctivitis sicca. This requirement can impact eligibility for coverage under specific plans.
Staying Updated on Medicare Coverage for Restasis
Importance of Regularly Checking Formularies
Beneficiaries should regularly check the most current version of their plan’s formulary, as coverage for Restasis and its tier placement can change. Medicare Part D and Medicare Advantage plans typically update their designs and formularies annually.
Availability of Generic Options
By early to mid-2026, generic cyclosporine 0.05% is expected to be widely available and preferred on many Medicare Part D plans, which could significantly affect coverage options and costs for beneficiaries.
Practical Tips for Navigating Medicare Coverage
Reviewing Plan Formularies
Beneficiaries should take the time to review their Medicare Part D or Medicare Advantage plan’s formulary to determine whether Restasis is covered. Understanding how Restasis is classified within the plan’s tier structure can help beneficiaries estimate potential copayments or coinsurance.
Contacting Customer Service for Clarification
For clarification on coverage rules and cost-sharing for Restasis, beneficiaries are encouraged to contact their plan’s customer service. Comparing different Medicare Part D or Medicare Advantage plans may also help beneficiaries find options that better manage the cost of Restasis.
Understanding Your Medicare Options for Restasis
Navigating coverage and costs for Restasis can be challenging, but staying informed about your plan’s formulary and coverage rules is essential. Regularly checking for updates can help manage costs and ensure access to necessary medications, allowing beneficiaries to make informed decisions about their healthcare.
Page content independently curated and maintained by David W. Bynon, Medicare Technical Operator, using a standardized, data-driven methodology designed for accurate, non-commercial Medicare plan interpretation and resolution.